The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction

Autor:	Carsten, Goessl, Leonid, Katz, William C, Dougall, Paul J, Kostenuik, Holly Brenza, Zoog, Ada, Braun, Roger, Dansey, Rachel B, Wagman
Rok vydání:	2012
Předmět:	Treatment Outcome Antineoplastic Agents Hormonal Drug Discovery RANK Ligand Animals Humans Osteoporosis Bone Neoplasms Bone Resorption Denosumab Antibodies Monoclonal Humanized
Zdroj:	Annals of the New York Academy of Sciences. 1263
ISSN:	1749-6632
Popis:	Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal-related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::9dca94d28299c241c6d83320d24c70a7 https://pubmed.ncbi.nlm.nih.gov/22831177 Zobrazit plný text záznamu Plný text